MODERNA INC (1MRNA.MI) Fundamental Analysis & Valuation

BIT:1MRNA • US60770K1079

Current stock price

42.465 EUR
-3.87 (-8.35%)
Last:

This 1MRNA.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. 1MRNA.MI Profitability Analysis

1.1 Basic Checks

  • 1MRNA had negative earnings in the past year.
  • 1MRNA had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: 1MRNA reported negative operating cash flow in multiple years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -22.87%, 1MRNA is in line with its industry, outperforming 53.75% of the companies in the same industry.
  • 1MRNA's Return On Equity of -32.62% is fine compared to the rest of the industry. 1MRNA outperforms 65.00% of its industry peers.
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROIC N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

1.3 Margins

  • 1MRNA has a Gross Margin of 70.32%. This is comparable to the rest of the industry: 1MRNA outperforms 58.75% of its industry peers.
  • 1MRNA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for 1MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1MRNA.MI Health Analysis

2.1 Basic Checks

  • 1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 1MRNA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 1MRNA has less shares outstanding
  • 1MRNA has a worse debt/assets ratio than last year.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.81 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 1MRNA (3.81) is better than 71.25% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that 1MRNA is not too dependend on debt financing.
  • 1MRNA's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. 1MRNA outperforms 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 3.81
ROIC/WACCN/A
WACC9.22%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • 1MRNA has a Current Ratio of 3.29. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
  • 1MRNA's Current ratio of 3.29 is fine compared to the rest of the industry. 1MRNA outperforms 72.50% of its industry peers.
  • 1MRNA has a Quick Ratio of 3.22. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
  • 1MRNA has a better Quick ratio (3.22) than 73.75% of its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.22
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. 1MRNA.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.66% over the past year.
  • 1MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.93%.
  • 1MRNA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.34% yearly.
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%

3.2 Future

  • 1MRNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.56% yearly.
  • Based on estimates for the next years, 1MRNA will show a very strong growth in Revenue. The Revenue will grow by 29.27% on average per year.
EPS Next Y6.26%
EPS Next 2Y14.9%
EPS Next 3Y15.65%
EPS Next 5Y20.56%
Revenue Next Year9.55%
Revenue Next 2Y13.08%
Revenue Next 3Y15.41%
Revenue Next 5Y29.27%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. 1MRNA.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • 1MRNA's earnings are expected to grow with 15.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.9%
EPS Next 3Y15.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1MRNA.MI Dividend Analysis

5.1 Amount

  • No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1MRNA.MI Fundamentals: All Metrics, Ratios and Statistics

MODERNA INC

BIT:1MRNA (3/30/2026, 7:00:00 PM)

42.465

-3.87 (-8.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)04-29
Inst Owners79.25%
Inst Owner ChangeN/A
Ins Owners2.7%
Ins Owner ChangeN/A
Market Cap16.77B
Revenue(TTM)1.94B
Net Income(TTM)-2.82B
Analysts56
Price Target36.86 (-13.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.99%
Min EPS beat(2)21.72%
Max EPS beat(2)76.27%
EPS beat(4)4
Avg EPS beat(4)37.2%
Min EPS beat(4)21.22%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)32.95%
EPS beat(12)10
Avg EPS beat(12)13.09%
EPS beat(16)12
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)9.26%
Min Revenue beat(2)6.17%
Max Revenue beat(2)12.36%
Revenue beat(4)3
Avg Revenue beat(4)10.37%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.33%
Revenue beat(12)11
Avg Revenue beat(12)27.78%
Revenue beat(16)13
Avg Revenue beat(16)23.1%
PT rev (1m)7.39%
PT rev (3m)23.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.79%
EPS NY rev (1m)4.18%
EPS NY rev (3m)4.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.18%
Revenue NY rev (1m)2.08%
Revenue NY rev (3m)6.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.91
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 2.25
EV/EBITDA N/A
EPS(TTM)-6.33
EYN/A
EPS(NY)-5.93
Fwd EYN/A
FCF(TTM)-4.58
FCFYN/A
OCF(TTM)-4.13
OCFYN/A
SpS4.29
BVpS19.07
TBVpS18.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.32%
FCFM N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.95%
Cap/Sales 10.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.22
Altman-Z 3.81
F-Score3
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)254.63%
Cap/Depr(5y)200.25%
Cap/Sales(3y)17.73%
Cap/Sales(5y)11.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
EPS Next Y6.26%
EPS Next 2Y14.9%
EPS Next 3Y15.65%
EPS Next 5Y20.56%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%
Revenue Next Year9.55%
Revenue Next 2Y13.08%
Revenue Next 3Y15.41%
Revenue Next 5Y29.27%
EBIT growth 1Y20.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.45%
EBIT Next 3Y20.09%
EBIT Next 5Y20.77%
FCF growth 1Y48.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.65%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / 1MRNA.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MODERNA INC?

ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI.


What is the valuation status for 1MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (1MRNA.MI). This can be considered as Overvalued.


What is the profitability of 1MRNA stock?

MODERNA INC (1MRNA.MI) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MODERNA INC?

The Earnings per Share (EPS) of MODERNA INC (1MRNA.MI) is expected to grow by 6.26% in the next year.